ABOUT US

For nearly 20 years, Amgen and UCB have worked together to research, develop, and market biologic products for the treatment of osteoporosis. At the center of this collaboration is a commitment to elevate osteoporosis as a chronic debilitating disease with the aim of improving post-fracture management in healthcare systems and increasing diagnosis and treatment of underlying osteoporosis.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World’s Best Workplaces™ by Fortune and Great Place to Work^® and one of the 100 most sustainable companies in the world by Barron’s.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

At UCB, we come to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. How we do business has been transformed and redesigned around the patient’s individual experience. Patients are at the heart of everything we do, inspiring us and driving our scientific discovery. By fulfilling our commitment and providing patients a meaningful experience, more impactful solutions are on the horizon.

With a team of approximately 8,300 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia and sites in Raleigh and Durham, North Carolina, Boston, Massachusetts, Seattle, Washington, and Washington, D.C.

For more information, visit www.ucb-usa.com and follow us on www.twitter.com/ucbusa.